KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Travere Therapeutics (TVTX) Cost of Revenue (2016 - 2025)

Travere Therapeutics (TVTX) has disclosed Cost of Revenue for 12 consecutive years, with $2.6 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cost of Revenue changed 0.0% year-over-year to $2.6 million, compared with a TTM value of $10.3 million through Dec 2025, up 33.51%, and an annual FY2025 reading of $10.3 million, up 33.51% over the prior year.
  • Cost of Revenue was $2.6 million for Q4 2025 at Travere Therapeutics, up from $1.6 million in the prior quarter.
  • Across five years, Cost of Revenue topped out at $4.7 million in Q1 2025 and bottomed at -$1.1 million in Q4 2021.
  • Average Cost of Revenue over 5 years is $2.0 million, with a median of $1.6 million recorded in 2021.
  • The sharpest move saw Cost of Revenue crashed 151.64% in 2021, then soared 425.81% in 2023.
  • Year by year, Cost of Revenue stood at -$1.1 million in 2021, then soared by 181.12% to $868000.0 in 2022, then skyrocketed by 425.81% to $4.6 million in 2023, then crashed by 44.06% to $2.6 million in 2024, then changed by 0.0% to $2.6 million in 2025.
  • Business Quant data shows Cost of Revenue for TVTX at $2.6 million in Q4 2025, $1.6 million in Q3 2025, and $1.5 million in Q2 2025.